Lori Muffly is a Hematology physician affiliated with Stanford Blood Center. OpenAlex indexes 455 publications with 5,810 citations (h-index 35); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Stanford, CA 943052200
Telephone
650-723-4000Provider last certified this registry record 15 Apr 2024.
Clinical trials
- Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Sponsor: Stanford University
- Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
Sponsor: Stanford University
- Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL
Sponsor: Stanford University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20255 payments
- Autolus IncProgram year20252 payments
- Gilead Sciences, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
44.9%Kinase inhibitor34.2%Jakafi100%Part D≥13 patientsSelective immunosuppressants7.4%Rezurock100%Part D<11 patients+ 1 more class in this area
Dermatology
32.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor32.6%Acyclovir100%Part D≥27 patientsAnti-infectives
16.3%Short-acting sulfonamides11.4%Sulfamethoxazole-Trimethoprim100%Part D≥12 patientsAzole Antifungal4.9%Posaconazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Andrew Rezvani, MD
Stanford Blood Center
Wen-Kai Weng, MD, PhD
Stanford Blood Center
Parveen Shiraz, MD
Stanford Blood Center
Hitomi Hosoya, MD
Stanford Blood Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”